Cargando…
The prognostic and predictive roles of plasma C‐reactive protein and PD‐L1 in non‐small cell lung cancer
BACKGROUND: Anti‐PD‐(L)1 agents have revolutionized the treatment paradigms of non‐small cell lung cancer (NSCLC), while predictive biomarkers are limited. It has been previously shown that systemic inflammation, indicated by elevated C‐reactive protein (CRP) level, is associated with a poor prognos...
Autores principales: | Kuusisalo, Saara, Tikkanen, Antti, Lappi‐Blanco, Elisa, Väisänen, Timo, Knuuttila, Aija, Tiainen, Satu, Ahvonen, Jarkko, Iivanainen, Sanna, Koivunen, Jussi P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469721/ https://www.ncbi.nlm.nih.gov/pubmed/37329173 http://dx.doi.org/10.1002/cam4.6262 |
Ejemplares similares
-
Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors
por: Iivanainen, Sanna, et al.
Publicado: (2019) -
Association of Rare Immune-Related Adverse Events to Survival in Advanced Cancer Patients Treated with Immune Checkpoint Inhibitors: A Real-World Single-Center Cohort Study
por: Kuusisalo, Saara, et al.
Publicado: (2022) -
Treatment discontinuation and re-initiation of anti-PD-(L)1 agents in metastatic cancers
por: Tikkanen, Antti, et al.
Publicado: (2020) -
Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection
por: Iivanainen, Sanna, et al.
Publicado: (2020) -
Follow-Up of Cancer Patients Receiving Anti-PD-(L)1 Therapy Using an Electronic Patient-Reported Outcomes Tool (KISS): Prospective Feasibility Cohort Study
por: Iivanainen, Sanna, et al.
Publicado: (2020)